Local complications associated with labial salivary gland biopsy for diagnosis of Sjögren’s Syndrome: A retrospective cohort study

Elena M. Varoni, Gabriele Villani, Niccolò Lombardi, Alberto Pispero, Giovanni Lodi, Andrea Sardella, Daniela Uglietti

Dipartimento di Scienze Biomediche, Chirurgiche ed Odontoiatriche, Università degli Studi di Milano, Milan, Italy

Correspondence:
Dipartimento di Scienze Biomediche
Chirurgiche ed Odontoiatriche
Università degli Studi di Milano
Via Beldiletto 1, 20142 Milano, Italy
andrea.sardella@unimi.it

Abstract
Background: To describe local or systemic complications related to the labial salivary glands biopsy (LSGB) used as diagnostic tool for the diagnosis of Sjögren’s Syndrome (SS).

Material and Methods: Clinical databases from a cohort of patients, who underwent LSGB with provisional clinical diagnosis of Sjögren’s Syndrome, were retrospectively reviewed. Pain, assessed by registering the intake of analgesic drugs in the first week following the biopsy, and any further relevant clinical information regarding complications after biopsy were recorded.

Results: 50 patients received LSGB. 10 of them (9 women and 1 man) showed histopathological findings compatible with SS. Ten patient (20%) receiving labial biopsy developed local complications: three of them (6%) reported a sensory defect at the surgical site that lasted at most few weeks; three patients (6%) reported pain sensation needing the assumption of analgesic drugs, while one patient (2%) described a transient local burning sensation, which resolved in few days. Three patients (6%) showed cutaneous haematoma in the surgical area and two patients (4%) showed mild mucosal inflammation at the biopsy site.

Conclusions: LSGB is associated with few and mild complications and it is a useful tool in the diagnosis of SS. The complications usually resolved in few weeks after the biopsy.

Key words: Sjögren’s syndrome, labial salivary glands biopsy, adverse events, diagnosis.

Introduction
Sjögren’s Syndrome (SS) is a chronic, autoimmune, rheumatic disease characterized by the lymphocytic-mediated destruction of exocrine glands, resulting in glandular dysfunction (1). It affects mainly Caucasian females, at age of 40-50 years (2). SS is typically characterized by xerostomia and xeroophthalmia (“sicca syndrome”), due to reduced glandular
Complications after labial salivary gland biopsy

Secretions. SS is also regarded as a multisystem disease, since it can affect other organs, such as lungs, kidneys, skin (1). In case of just secretory glands involvement, thus without the concomitant occurrence of further chronic inflammatory autoimmune disorders, this syndrome is known as primary Sjögren’s syndrome (pSS), while, when in association with other systemic connective tissue diseases, it is known as secondary Sjögren’s syndrome (sSS) (3).

Among oral symptoms, besides xerostomia, patients with SS usually complain dysgeusia, oral burning sensation, difficulty in swallowing food, problems in using removable dental prosthesis. These patients are also at high risk of dental caries (4) and oral candidiasis infections (5). All together, these signs and symptoms strongly decrease the health-related quality of life of SS patients, with important impact on the emotional and psychological spheres (6). Furthermore, epidemiological data emphasized their higher risk of developing a mucosal-associated lymphoid tissue (MALT) lymphoma (7).

The final diagnosis of SS is complex and multi-steps; it is chiefly achieved by rheumatologists, in teamwork with ophthalmologists and oral medicine/pathology specialists. In 2016, the American College of Rheumatology and the European League Against Rheumatism developed and validated an updated set of classification criteria, based on the weighted sum of the following 5 items (Table 1): anti-SSA/Ro antibody positivity, focal lymphocytic sialadenitis, abnormal ocular staining score, reduced Schirmer’s test, and reduced unstimulated whole saliva flow (7).

### Table 1: The classification criteria for SS, modified from Shiboski 2017 (1).

| Item                                      | Score |
|-------------------------------------------|-------|
| Labial salivary gland biopsy (LSGB)*      | 3     |
| Anti-SSA/Ro positive                      | 3     |
| Ocular Staining Score †                   | 1     |
| Schirmer’s test ‡                         | 1     |
| Reduced unstimulated whole saliva flow ‡  | 1     |

*Labial salivary gland with focal lymphocytic sialadenitis and focus score of ≥1 foci/4 mm² †Ocular Staining Score ≥5 (or van Bijsterveld score ≥4) in at least 1 eye ‡Schirmer’s test ≤ 5 mm/5 minutes in at least 1 eye ‡χ rate: ≤ 0.1 ml/minute

Periductal or perivascular level (8). LSGB in the diagnosis of SS plays a key role and it is widely applied in the clinical settings. In the last decades, some Authors also suggested the use of parotid gland as the organ of choice for investigating salivary gland involvement in SS, since major salivary glands, especially parotids, could be earlier and more frequently involved than the minor ones (7). Although parotid biopsy shows comparable sensibility and specificity to LSGB, it requires a more experienced operator. Parotid biopsy’s potential complications include facial nerve damage, cutaneous fistulae, scarring, or temporary change in sensory sensation of the skin in the area of the incision (9-11). To date, just few centers use this technique.

The aim of this study was to evaluate local complications of LSGB used in the diagnostic algorithm of SS.

### Material and Methods

- **Study design, population and setting**
  In this observational cohort study, we retrospectively reviewed the clinical databases of patients who underwent LSGB, at Unità di Medicina Orale (San Paolo Hospital, Milan, Italy). For all of them the provisional clinical diagnosis was Sjögren’s Syndrome. 50 patients were enrolled, in a consecutive order and without any exclusion criteria, over a period of 36 months from 2015 to 2018. None salivary gland biopsy was previously performed on these patients.

  Each patient had signed two informed consents: the first one was related to privacy and data collection while the second one was related to the bioptic surgical procedure.

- **Surgical procedure**
  After written informed consent, in all cases, the LSGB included a preliminary oral rinse with 0.2% chlorhexidine, then local anesthesia was performed by infiltration of 2% mepivacaine with vasoconstrictor (1:200.000 adrenaline); a single horizontal incision of about 1 – 1.5 cm of length between the midline and commissure of the lower labial mucosa was carried out, on clinically healthy labial mucosa. After removal of minor salivary glands, the surgical flaps were closed by black silk suture 4/0.

  At the end of each biopsy, the patient received detailed post-surgical indications recommending to apply topical 1% chlorhexidine gel (twice a day for 7 days), not to smoke for at least 7 days and to avoid hot foods for 48 hours.

  The suture was removed seven days after the surgical procedure, when local complications were recorded during the clinical evaluation.

- **Data collection**
  The complete clinical history of each patient, including systemic diseases, pharmacological therapies and demographic data, was recorded.

  Sialometry, as clinical step during diagnostic assessment, was also recorded for each patient, to verify the...
flow rate of the whole saliva (normal values: 0.2-0.5 ml/min), both unstimulated and stimulated by spitting method (12). When available, results from the Schirmer’s test, performed by the ophthalmologist to verify xerophthalmia, were further collected. Report ed pain, assessed by registering the intake of analgesic drugs in the first week following the biopsy, was recorded, as any further relevant information regarding post-operative complications. 

Statistical analysis
-Data were analyzed by means of descriptive statistics. Age was expressed as mean and standard deviation (mean ± SD). Prevalence of complication was expressed as percentage (%).

Results
Data from 50 patients were reviewed. They were 45 women and 5 men (female: male ratio = 9:1), with a mean age of 56.1±14.4 years (range 24-85). 17 of them had at least one systemic autoimmune disease that was already diagnosed (2 patients were affected by other two concomitant autoimmune disease) (Table 2, 2 cont.). Eight patients had xerostomia objectively confirmed by sialometry; in 6 patients the Schirmer’s test was also positive. No patient needed the assumption of antibiotics after the LSGB. All specimens obtained by biopsy were adequate for histopathological analysis. Of the 50 patients biopsied, one received the final diagnosis of Mikulicz’s disease (MD), while 10

| Patients | Sex | Age | Autoimmune disease | Complications | Histopathological findings compatible with SS |
|----------|-----|-----|---------------------|---------------|---------------------------------------------|
| 1        | F   | 60  | RA                  | N             |                                             |
| 2        | F   | 34  |                     | N             |                                             |
| 3        | F   | 63  |                     | N             |                                             |
| 4        | F   | 63  |                     | P             |                                             |
| 5        | F   | 67  | PSS / RA            | BS            | SS                                          |
| 6        | F   | 72  |                     | H             | SS                                          |
| 7        | F   | 31  | SLE                 | N             |                                             |
| 8        | F   | 24  |                     | N             |                                             |
| 9        | M   | 85  |                     | N             |                                             |
| 10       | F   | 52  | CTD                 | N             |                                             |
| 11       | F   | 40  |                     | N             |                                             |
| 12       | F   | 37  |                     | N             | SS                                          |
| 13       | F   | 68  |                     | N             |                                             |
| 14       | F   | 48  |                     | N             |                                             |
| 15       | F   | 52  | HT                  | N             |                                             |
| 16       | F   | 52  |                     | N             |                                             |
| 17       | F   | 63  |                     | N             | MD                                          |
| 18       | F   | 66  | HT                  | N             |                                             |
| 19       | F   | 60  |                     | N             |                                             |
| 20       | F   | 54  | MI                  |               |                                             |
| 21       | F   | 48  |                     | N             |                                             |
| 22       | M   | 43  |                     | N             |                                             |
| 23       | F   | 45  | RA                  | N             | SS                                          |
| 24       | F   | 60  | P / SD              |               |                                             |
| 25       | M   | 70  |                     | N             |                                             |
| 26       | F   | 48  |                     | N             |                                             |
| 27       | F   | 31  | SLE                 | N             |                                             |
| 28       | F   | 37  |                     | P             |                                             |
| 29       | F   | 70  |                     | N             |                                             |

Table 2: Demographic data, clinical findings and post-surgical complications in 50 patients who underwent labial salivary gland biopsy (LSGB).
patients (9 women and 1 man) had histopathological findings compatible with SS.

Ten of the total 50 patients (20%) receiving labial biopsy developed local complications (Table 3). Three patients (6%) reported temporarily local dysesthesia; the latter was localized to a small area of the labial mucosa and lasted few weeks and was followed by a higher sensation than normal. In all cases completely normal sensation was recovered in few months. Further three patients (6%) reported a pain needing the assumption of an analgesic drug, which resolved within 2 days after biopsy; one patient (2%) described a transient local burning sensation, not requiring any drug intake. Three patients (6%) showed cutaneous haematoma in correspondence of surgical intervention, while two patients (4%) showed mild mucosal inflammation at the biopsy site. Only two of the patients, who developed temporarily local dysesthesia, reported the concomitant presence of a second local complication: mild inflammation in the first case and pain in the second one.

Two patients with post-operative complications were positive for SS (one reporting burning sensation, while one hematoma).

**Discussion**

LSGB is a useful and easy method to investigate salivary gland involvement in patient with suspected SS (9,13-
15). In this study, all the specimens were, indeed, considered sufficient for the diagnosis by pathologists. Lip biopsy can quickly be performed with minimal discomfort for the patient because glands are widely distributed, they have an easy access, and can provide adequate tissue sample for histopathological analysis (9). A focus score ≥1 foci/4 mm² on LSGB is one of the European classification criteria for the diagnosis of pSS (Table 1).

Although not uncommon (ten patients in our cohort of 50 patients: 20%), in the present study local complications of LSGB, recorded 7 days after the biopsy, were just of minor entity, without long-term sequelae. Therapy, when required, involved the local application of antiseptic agent (chlorhexidine) for a period longer than 1 week or the assumption of analgesic drugs. Other studies showed even lower percentage of short- and medium-term complications, with rates ranging from 8.1% (16) to 11.5% (17).

One of the mostly reported complication was a reduced sensitivity over a small area of labial mucosa at biopsy site (3 patients out of 50: 6%), a complication that encountered also in the surgical treatment of labial mucoceles (18). The sensory disturbances lasted from few weeks until few months, and usually did not cause difficulty or distress, as long as the patient was informed about this specific adverse event, before performing the biopsy. Partial loss of lip sensitivity was recorded also by other Authors after LSGB: 2 patients out of 58 (3.4%) reported by Richards et al. (14); 3 patients out of 362 (1.1%) by Daniels and colleagues (15) and 3 patients out of 79 (3.8%) recorded by Marx et al. (7). A retrospective analysis (17) described the lip paraesthesia, in the first week after LSGB, in 8.2% (n=452) of patients; after 7 days, 3.5% of these patients still had paraesthesia which resolved in few weeks, and only one of them (0.2%) had a long-term paraesthesia. The complete normal sensitivity is usually restored within a few weeks, although long-lasting impaired sensory defects have been rarely reported. Richards et al. (14) described one case of sensory defect that persisted for more than one year, while another study (7) showed one patient with anaesthesia persisting for more than 2 years. A comparative study, comparing LSGB and sublingual salivary gland biopsy, reported one case of permanent anaesthesia after LSGB (19).

Pain was a further reported complication, in our study occurring in 3 patients (6%) and lasting maximum for 2 days. Pain was easily controlled by the intake of analgesic drugs as NSAIDs. Most of literature showed similar findings: Friedman et al. (20) reported only one case out 118 patients (0.8%) of pain immediately after the biopsy, and 3 cases (2.5%) after one week. In the study by Lida-Santiago et al. (16) involving 186 individuals, 12 patients (7.32%) still had pain after 7 days, lasting at most 1 month. Only one study reported a higher percentage (11): 11 patients out of 35 (31%) experienced some pain after the biopsy, which resolved in all cases within in month.

Furthermore, some cases of cutaneous haematoma (3 patients out of 50: 6%) and mild inflammation (2 patients out of 50: 4%) at the biopsy site were recorded. These side-effects were always of small entity, and healed in a few days spontaneously. These signs were reported also by other authors (15-17), with similar clinical course.

One third of the patients included in the study (17 out of 50 patients: 34%) showed at least one additional autoimmune disease, reported in the following list: rheumatoid arthritis (RA), progressive systemic sclerosis (PSS), primary biliary cirrhosis (PBC), connective tissue disease (CTD), Hashimoto’s thyroiditis (HT), systemic lupus erythematosus (SLE).

Among the ten patients who developed post-operative complications only three of them were affected by other autoimmune diseases: progressive systemic sclerosis and rheumatoid arthritis in the first case, primary biliary cirrhosis in the second one and rheumatoid arthritis in the third case.

Other very rare complications found in literature were pyogenic granuloma, with prevalence varying from 0.5% (21) to 1.22% of cases (16), suture failure in 3.4% (20), local swelling in 24 patients out of 452 (5.3%) (17) and syncope in 6 patients out of 186 (3.2%) (16). On the other hand, some Authors did not report any complication after LSGB, except for mild discomfort at the biopsy site lasting up to one week (10). A specific informed consent before performing the surgical procedure is always recommended in order to minimize the patients’ distress in case of post-operative complications.

Within the limitations of this work, which are mainly related to the retrospective approach of this study, to the small size of the sample and to the surgical procedures performed by different oral surgeons with variable clinical experience, this cohort study confirms that LSGB is an easy and useful tool for the diagnosis of SS. This diagnostic method, compared to the more invasive and risky parotid gland biopsy, it’s associated with minor complications. When occurring, they are mostly mild and can be resolved within few weeks. The biopsy of the lip is usually well-accepted by patients perceiving this technique as minimally invasive, with a low risk of complications.

In conclusion, this work confirms that, consistently with previous literature, LSGB is a useful tool for the diagnosis of SS, since it is mainly associated with reliable accuracy and minor local complications.

References
1. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. International Sjögren’s Syndrome Criteria Working Group. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: A consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017;76:9-16.
2. Patel R, Shahane A. The epidemiology of Sjögren’s syndrome. Clin Epidemiol. 2014;6:247-255
3. Aggarwal R, Anaya JM, Koelsch KA, Kurien BT, Scofield RH. Association between Secondary and Primary Sjögren’s Syndrome in a Large Collection of Lupus Families. Autoimmune Dis. 2015;2015:298506.

4. Zero DT, Brennan MT, Daniels TE, Papas A, Stewart C, Pinto A, et al. Sjögren’s Syndrome Foundation Clinical Practice Guidelines Committee. Clinical practice guidelines for oral management of Sjögren disease: Dental caries prevention. J Am Dent Assoc. 2016;147:295-305.

5. Soto-Rojas AE, Villa AR, Sifuentes-Osorio J, Alarcón-Segovia D, Kraus A. Oral candidiasis and Sjögren’s syndrome. J Rheumatol. 1998;25:911-5.

6. Kotsis K, Voulgaris PV, Tsifetaki N, Drosos AA, Carvalho AF, Hyphantis T. Illness perceptions and psychological distress associated with physical health-related quality of life in primary Sjögren’s syndrome compared to systemic lupus erythematosus and rheumatoid arthritis. Rheumatol Int. 2014;34:1671-81.

7. Marx RE, Hartman KS, Rethman KV. A prospective study comparing incisional labial to incisional parotid biopsies in the detection and confirmation of sarcoidosis, Sjögren’s disease, sialosis and lymphoma. J Rheumatol. 1988;15:621-9.

8. Fisher BA, Jonsson R, Daniels T, Bombardieri M, Brown RM, Morgan P, et al. Sjögren’s histopathology workshop group (appendix) from ESSENTIAL (EULAR Sjögren’s syndrome study group). Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren’s syndrome. Ann Rheum Dis. 2017;76:1161-1168.

9. Spijkervet FK, Haacke E, Kroese FG, Bootsmma H, Vissink A. Parotid Gland Biopsy, the Alternative Way to Diagnose Sjögren Syndrome. Rheum Dis Clin North Am. 2016;42:485-99.

10. Wise CM, Agudelo CA, Semble EL, Stump TE, Woodruff RD. Comparison of parotid and minor salivary gland biopsy specimens in the diagnosis of Sjögren’s syndrome. Arthritis Rheum. 1988;31:662-6.

11. Piipe J, Kalk WW, van der Wal JE, Vissink A, Kluin PM, Roodenburg JL, et al. Parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjogren’s syndrome. Rheumatology (Oxford). 2007;46:335-41.

12. Varoni EM, Federighi V, Decani S, Carrassi A, Lodi G, Sardella A. The effect of clinical setting on the unstimulated salivary flow rate. Arch Oral Biol. 2016;69:7-12.

13. van Stein-Callenfels D, Tan J, Bloemena E, van Vugt RM, Voskuyl AE, Santana NT, et al. The role of a labial salivary gland biopsy in the diagnostic procedure for Sjögren’s syndrome; a study of 94 cases. Med Oral Patol Oral Cir Bucal. 2014;19:e372-6.

14. Richards A, Mutlu S, Scully C, Maddison P. Complications associated with labial salivary gland biopsy in the investigation of connective tissue disorders. Ann Rheum Dis. 1992;51:996-7.

15. Daniels TE. Labial salivary gland biopsy in Sjögren’s syndrome. Assessment as a diagnostic criterion in 362 suspected cases. Arthritis Rheum. 1984;27:147-56.

16. Lida Santiago M, Seisdedos MR, Garcia Salinas RN, Secco A, Marino Claverie L, Tchera L, et al. Frequency of complications and usefulness of the minor salivary gland biopsy. Reumatol Clin. 2012;8:255-8.

17. Caporali R, Bonacci E, Epis O, Bobbio-Pallavicini F, Mombini P, Monteucco C. Safety and usefulness of minor salivary gland biopsy: retrospective analysis of 502 procedures performed at a single center. Arthritis Rheum. 2008;59:714-20.

18. Re Cecconi D, Aciellhi A, Tarozzi M, Lodì G, Demarosi F, Sardella A, Carrassi A. Mucoceles of the oral cavity: A large case series (1994-2008) and a literature review. Med Oral Patol Oral Cir Bucal. 2010;15:e551-6.

19. Berquin K, Mahy P, Weynand B, Reyucher H. Accessory or sublingual salivary gland biopsy to assess systemic disease: a comparative retrospective study. Eur Arch Otorhinolaryngol. 2006;263:233-6.

20. Friedman JA, Miller EB, Huszar M. A simple technique for minor salivary gland biopsy appropriate for use by rheumatologists in an outpatient setting. Clin Rheumatol. 2002;21:349-50.

21. Teppo H, Revonta M. A follow-up study of minimally invasive lip biopsy in the diagnosis of Sjögren’s syndrome. Clin Rheumatol. 2007;26:1099-103.

Conflict of interest
The authors declare no conflict of interest.